NEW YORK-- Shares of Ambit Biosciences tumbled Wednesday after the company said it won't file for accelerated approval of its leukemia drug quizartinib, and will run a late-stage clinical trial instead. The company has been meeting with the Food and Drug Administration to discuss quizartinib, a potential treatment for acute myeloid leukemia.» Read More
Why wouldn’t they? They’ve made a lot of money during this downturn. But that might be changing now.
Speculation offers the chance for big returns, which is just the thing investors need right now.
This company has heart, Cramer says. Find out how BSX fought its way off the operating table.
It’s easy to like a company that, even in this environment, is focused on taking share.
CEO David Pyott tells investors to think of more than just Botox when his company is mentioned.
The Democrats aren’t the only enemy of Big Pharma. The Fourth Estate has its own crusade against the group.
This is how you balance Mad Money stock picks with your own portfolio.
This biotech sells its treatment to a niche clientele for big money.
Vertex Pharma is lagging its peers. But biotech is so good right now, it might not matter.
Genzyme may make orphan drugs, but this company is a lot closer to Daddy Warbucks.
Cramer offers up five reasons why this sector is the best one to own through the fall. Plus, the top stocks in the group.
Why's the market up after such horrible earnings? Black gold, that's why.
Cramer ventures a guess as to who's next on the takeover list.
Boston Scientific quarterly earnings fell 15 percent on declining sales of its drug-eluting stents and charges for acquisitions, divestitures and restructuring.
Also, how to play next week's busy schedule of earnings.
Drug developer Eli Lilly will buy SGX Pharmaceuticals for about $64 million in cash in an effort to expand its drug discovery efforts, the companies said Tuesday.
Cramer continued with his "Cramerican Marine Field Guide to Recessions" reflecting on the 1990 Playbook (the last time we had a financial meltdown) where healthcare stocks, especially biotech were the winners then, and in Cramer's view are likely to do it again.
Cramer tells what works in the Wall Street fashion show, what gets the big money guys to turn their heads and say, “ah, I want to own that right now,” or "I want to dump that right now", for the exact situation we’re facing.
That's what worked in 1990, in an environment much like this one.
Medicis Pharma could have such a product on the market by 2011.